Quince Therapeutics (QNCX): An Unsuccessful Long Game

The company, Quince Therapeutics (NASDAQ: QNCX), is trialling a relatively niche drug called NEAT. The purpose of the drug is to reduce, stop, and even improve symptoms that are experienced by ataxia-telangiectasia (A-T) sufferers. This affects roughly 0.00175% of people; however, there isn’t any treatment that has shown statistical significance in treating it. They are currently the frontrunner in this and have said they expect topline results in Q1 2026.

Current market cap of Quince Therapeutics is 215mil. Market valuation for treatment of such a disease is hard to gauge, but if NEAT becomes the only medication of its kind, then they would have the monopoly.

There was an upcoming catalyst for the stock that, should it have been successful, would have increased the share price over 1000% within a short space of time. Unfortunately, this did not play out despite the confidence of the CEO in interviews in the lead-up to the data readout.

Alerted entry to our premium members. Once the news dropped of missing primary endpoints then an alert went out quickly so that our members could get out of the trade.